ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PSMA/Anti-CD3 Dual-masked T-cell Engager JANX014

Its studies are mostly in Prostatic Neoplasms, led by Janux Therapeutics.

Furthest: phase 1, since Apr 16, 20261 company-led study, 1 open or runningNext primary completion: May 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Janux Therapeutics11 open or runningphase 1since Apr 16, 2026Apr 16, 2026May 2028phase 1 · NCT07545811

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 16, 2026First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT07545811 · 43 planned · United States

Ahead

  1. May 2028Primary completion: phase 1 study in Prostatic NeoplasmsNCT07545811

TargetBeta

CD3E →FOLH1 →read by rule
“A tumor-activated, double-masked T-cell engager (TCE) directed against the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the CD3 antigen found on T-lymphocytes, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
olsutamigruleRegeneron Pharmaceuticalsphase 22
Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514ruleGlaxoSmithKlinephase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07545811Prostatic Neoplasms · United States1RecruitingMay 202843

How it is read

Names in the registry

  • “JANX014”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.